PolyPid Completes FDA New Drug Application for D-PLEX 100
Summary
PolyPid has completed its New Drug Application (NDA) submission to the FDA for D-PLEX 100, a significant step towards potential market approval for its lead product.
Key Events
-
NDA Submission Completed
PolyPid announced the successful completion of its New Drug Application (NDA) submission to the FDA for D-PLEX 100, its lead product candidate for the prevention of surgical site infections.
-
PDUFA Target Date Set
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for the first quarter of 2027 for D-PLEX 100, indicating a timeline for a potential approval decision.
-
Supported by Positive Phase 3 Data
The NDA is backed by positive results from the pivotal Phase 3 SHIELD II trial, which demonstrated a 60% relative risk reduction in surgical site infections compared to standard of care.
-
Expedited Review Designations
D-PLEX 100 holds Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations from the FDA, supporting eligibility for Priority Review.
Analysis
PolyPid has successfully completed its New Drug Application (NDA) submission to the FDA for D-PLEX 100, its lead product candidate for preventing surgical site infections. This marks a critical regulatory milestone, moving the company closer to potential commercialization. The FDA has set a PDUFA target action date for the first quarter of 2027, providing a clear timeline for a potential approval decision.
At the time of this filing, PYPD was trading at $4.85 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $90.1M. The 52-week trading range was $2.44 to $5.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.